Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EBP | Q15125 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031756 | 0.81 | BCHE (0.43) | BCHETSHRHSD17B10HRH3CYP1A2 | |
| SCHEMBL1033025 | 0.79 | BCHE (0.41) | BCHETSHRHSD17B10MAOBHRH3 | |
| SCHEMBL1031781 | 0.76 | BCHE (0.41) | BCHETSHREBPTMEM97SIGMAR1 | |
| SCHEMBL13450920 | 0.71 | BCHE (0.57) | BCHETSHRHSD17B10MAOBCYP1A2 | |
| SCHEMBL330083 | 0.71 | HRH3 (0.68) | BCHETSHRHSD17B10HRH3 | |
| Water SCHEMBL28117059 | 0.69 | HRH3 (0.65) | BCHETSHRHSD17B10HRH3 | |
| Hydrochloric Acid SCHEMBL17710415 | 0.69 | HRH3 (0.65) | BCHETSHRHSD17B10HRH3 | |
| SCHEMBL14637630 | 0.68 | UHRF1 (0.52) | TSHRHSD17B10 | |
| SCHEMBL31554587 | 0.68 | UHRF1 (0.52) | TSHRHSD17B10 | |
| SCHEMBL1030184 | 0.68 | TXNRD1 (0.43) | BCHECYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383641-B2 | Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-02-26 | — | — | US | disclosed |
| EP-2013179-B1 | ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-01-19 | — | — | EP | disclosed |
| US-20090143383-A1 | ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143383-A1 | ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | SLC6A3, DRD3, MC3R | BCHE 1283/4885TSHR 127/4885HSD17B10 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.